Results 201 to 210 of about 74,688 (254)

Integrated proteomic analysis identifies TYMS-dependent AMPK-mTOR signaling in pancreatic neuroendocrine tumors. [PDF]

iScience
Vijayakurup V, Meyer B, Rizvi SR, Kievit KH, Hyder I, Koh J, Feely M, Guijarro MV, Kaye FJ, Zajac-Kaye M.   +9 more
europepmc   +1 more source

Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice. [PDF]

PLoS One
Cambier A, Da Silva J, Bex J, Canesi F, Neanne LL, Sannier A, Mathieu H, Boedec E, Badie A, Monteiro RC.   +9 more
europepmc   +1 more source

Peripheral artery disease and local drug delivery: a review of disease pathology and drug delivery systems for therapy below the knee. [PDF]

Exp Biol Med (Maywood)
Akers NM, Dugas TR.
europepmc   +1 more source

Application of population pharmacokinetic modeling of SVG-101 to evaluate proper dose selection. [PDF]

Transl Clin Pharmacol
Mo KH, Chae D, Jung YS, Jin BH, Keum DH, Choi MK, Cha JS, Park MS, Kim CO.   +8 more
europepmc   +1 more source

Clinical complete response achieved in patients with breast cancer liver metastasis after personalized treatment: a case report and literature review. [PDF]

Front Oncol
Wang Y, Jing N, Wang Y, Li N.
europepmc   +1 more source

Topical Application of Everolimus Attenuates Lens-Induced Myopia Through mTORC1 Suppression. [PDF]

Invest Ophthalmol Vis Sci
Zhang R, Yu C, Li Y, Dong J, Wu H, Yang Y, Shi X, Zhou W, Zhao H, Cai B, Wang S, Dong L, Shao L, Li W, Jonas JB, Wei W.   +15 more
europepmc   +1 more source

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma. [PDF]

Clin Exp Med
Sun Y, Cheng Q, Zhou Q, Xu Y, Wang G, Xu C, Wang W, Cai S, Chen W.   +8 more
europepmc   +1 more source

Ultra-low thickness bio-degradable polymer vs durable polymer everolimus eluting stents - A 24 months clinical follow-up study. [PDF]

Indian Heart J
Kaul U, Garg PK, Chopra R, Gupta R, Mathur V.   +4 more
europepmc   +1 more source

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

, 2016
David Neal Franz, Е. Д. Белоусова, Steven Sparagana, E. Martina Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael Kohrman, J. Robert Flamini, Joyce Y. Wu, Paolo Curatolo, Petrus J. de Vries, Noah Berkowitz, Julie Niolat, Sergiusz Jóźwiak   +14 more
openalex   +2 more sources

Disproportionality Analysis of Oral Toxicities Associated with PI3K/AKT/mTOR Pathway Inhibitors Using the FAERS Database. [PDF]

Pharmaceuticals (Basel)
Marni M, Simoens D, Romero N, Jones WK, Kaja S.   +4 more
europepmc   +1 more source